share_log

B. Riley Securities Maintains Buy on Journey Medical, Raises Price Target to $6

Benzinga ·  Jul 12, 2023 22:47

B. Riley Securities analyst Kalpit Patel maintains Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $3 to $6.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment